Human respiratory syncytial virus and other viral infections in infants receiving palivizumab

Journal of Clinical Virology

Volumn 42, Issue 1, 2008, Pages 52-57

  Boivin, Guy ^a,b   Caouette, Georges ^b,c   Frenette, Line ^b,c   Carbonneau, Julie ^a   Ouakki, Manale ^d   De Serres, Gaston ^b,d  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Sainte Foy Pediatric Clinic   (Canada)

^d Public Health Research Unit   (Canada)

Author keywords

Human respiratory syncytial virus; Palivizumab; Resistance

Indexed keywords

PALIVIZUMAB;

AMPLICON; ARTICLE; BRONCHIOLITIS; CHILD; CONTROLLED STUDY; DRUG BINDING SITE; FEVER; FUSION GENE; GENE MUTATION; GENE SEQUENCE; HOSPITALIZATION; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MAJOR CLINICAL STUDY; METAPNEUMOVIRUS; PNEUMONIA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS CULTURE; VIRUS DETECTION; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA B VIRUS; MALE; METAPNEUMOVIRUS; NASOPHARYNX; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RESPIRATORY TRACT INFECTIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRUS DISEASES;

EID: 42649116771     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcv.2007.11.012     Document Type: Article

References (20)

1. Beeler J.A., and van Wyke Coelingh K. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63 (1989) 2941-2950
2. Boivin G., De Serres G., Cote S., Gilca R., Abed Y., Rochette L., Bergeron M.G., and Dery P. Human metapneumovirus infections in hospitalized children. Emerg Infect Dis 9 (2003) 634-640
3. DeVincenzo J.P., Hall C.B., Kimberlin D.W., Sanchez P.J., Rodriguez W.J., Jantausch B.A., Corey L., Kahn J.S., Englund J.A., Suzich J.A., Palmer-Hill F.J., Branco L., Johnson S., Patel N.K., and Piazza F.M. Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis 190 (2004) 975-978
4. Feltes T.F., Cabalka A.K., Meissner H.C., Piazza F.M., Carlin D.A., Top Jr. F.H., Connor E.M., and Sondheimer H.M. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 143 (2003) 532-540
5. Greenough A. Respiratory syncytial virus infection: clinical features, management, and prophylaxis. Curr Opin Pulm Med 8 (2002) 214-217
6. Hamelin M.E., Cote S., Laforge J., Lampron N., Bourbeau J., Weiss K., Gilca R., DeSerres G., and Boivin G. Human metapneumovirus infection in adults with community-acquired pneumonia and exacerbation of chronic obstructive pulmonary disease. Clin Infect Dis 41 (2005) 498-502
7. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 (1998) 531-537
8. Jartti T., van den Hoogen B., Garofalo R.P., Osterhaus A.D., and Ruuskanen O. Metapneumovirus and acute wheezing in children. Lancet 360 (2002) 1393-1394
9. Johnson S., Griego S.D., Pfarr D.S., Doyle M.L., Woods R., Carlin D., Prince G.A., Koenig S., Young J.F., and Dillon S.B. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 180 (1999) 35-40
10. Johnson S., Oliver C., Prince G.A., Hemming V.G., Pfarr D.S., Wang S.C., Dormitzer M., O'Grady J., Koenig S., Tamura J.K., Woods R., Bansal G., Couchenour D., Tsao E., Hall W.C., and Young J.F. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176 (1997) 1215-1224
11. Meissner H.C. Selected populations at increased risk from respiratory syncytial virus infection. Pediatr Infect Dis J 22 (2003) S40-S44
12. Mejias A., Chavez-Bueno S., Rios A.M., Aten M.F., Raynor B., Peromingo E., Soni P., Olsen K.D., Kiener P.A., Gomez A.M., Jafri H.S., and Ramilo O. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 49 (2005) 4700-4707
13. Ogra P.L. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 5 (2004) S119-S126
14. Piedra P.A., Jewell A.M., Cron S.G., Atmar R.L., and Glezen W.P. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21 (2003) 3479-3482
15. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., and Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289 (2003) 179-186
16. Welliver R.C. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 22 (2003) S6-S12
17. Williams J.V., Harris P.A., Tollefson S.J., Halburnt-Rush L.L., Pingsterhaus J.M., Edwards K.M., Wright P.F., and Crowe Jr. J.E. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 350 (2004) 443-450
18. Zhao X., Chen F.P., Megaw A.G., and Sullender W.M. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 190 (2004) 1941-1946
19. Zhao X., Chen F.P., and Sullender W.M. Respiratory syncytial virus escape mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology 318 (2004) 608-612
20. Zhao X., and Sullender W.M. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 79 (2005) 3962-3968